This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 1, 2013 /PRNewswire/ -- Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Southern District of
New York, case no. 13 Civ. 0755, on behalf of all persons who purchased Keryx Biopharmaceuticals, Inc. ("Keryx" or the "Company") (NASDAQ CM: KERX) securities between
June 1, 2009 and
April 1, 2012 inclusive (the "Class Period").
If you wish to obtain information concerning this action or view a copy of the complaint, you can do so by clicking here:www.faruqilaw.com/KERX
Keryx and its Chief Executive Officer
Ron Bentsur are alleged to have violated Section 10(b) and/or 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Specifically, the complaint alleges that defendants mislead investors about the timing and success of Keryx's clinical trial that tested whether the drug perifosine was effective in treating late stage colorectal cancer.
April 2, 2012, Keryx announced the top-line data from the perifosine X-PECT Phase 3 Clinical Trial. The Company revealed that the trial for refractory advanced colorectal cancer did not meet the primary endpoint of improving overall patient survival versus capecitabine and a placebo. On this disappointing news, Keryx share price plummeted from
March 30, 2012 to
April 2, 2012 – a decline of roughly 65%.
Plaintiff now seeks to recover damages on behalf of himself and all other individual and institutional investors who bought Keryx securities between
June 1, 2009 and
April 1, 2012, excluding defendants and their affiliates. Plaintiff is represented by Faruqi & Faruqi, LLP, a law firm with extensive experience in prosecuting class actions and actions involving corporate fraud.
If you purchased Keryx securities during the Class Period, you may, not later than
April 2, 2013, move the court to serve as lead plaintiff of the class, if you so choose. In order to discuss this action, or if you have any questions concerning this notice or your rights or interests, please contact
FARUQI & FARUQI, LLP 369 Lexington Avenue, 10th Floor
New York, NY 10017 Attn:
Richard Gonnello, Esq.firstname.lastname@example.orgFrancis McConville, Esq.email@example.com Telephone: (877) 247-4292 or (212) 983-9330
SOURCE Faruqi & Faruqi, LLP